Viking therapeutics aktie

Cookie Einstellungen. Marketing- und Statistik-Cookies kommen nicht zum Einsatz.

Up to The Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints, with patients receiving VK demonstrating statistically significant reductions in body weight compared with placebo. Additionally, the study showed VK treatment to be safe and well tolerated with the majority of treatment emergent adverse events TEAEs being categorized as mild or moderate. Patients receiving weekly doses of VK demonstrated statistically significant reductions in mean body weight after 13 weeks, ranging up to Patients receiving VK also demonstrated statistically significant reductions in mean body weight relative to placebo, ranging up to

Viking therapeutics aktie

.

Artikel bewerten:. Nachrichten Nachrichten Nachrichten auf FN. PR Newswire

.

Hier stellen wir 8 Kommentare aus der Community passend zu Viking Therapeutics vor, die von Nutzer:in als besonders interessant, informativ oder als gute Chartanalyse bewertet wurden. UTP Consolidated Nasdaq 3. NYSE 1. Tradegate Gettex London 8. Frankfurt 2. Stuttgart Stk. Berlin 17 Stk.

Viking therapeutics aktie

Viking Therapeutics Inc. GLP stands for glucagon-like peptide. All 10 analysts polled by FactSet have a buy or equivalent rating on the stock, even though Viking does not yet have a fully approved product on the market. But analysts led by Akash Tewaria acknowledged the trial data were impressive. Subscribe on Spotify and Apple. Canada Pension Plan, one of the largest in the world, doubled its investment in Apple stock, initiated a position in Alibaba, and bought more Microsoft and Tesla.

Teria yabar

Bestbewertete News. Erweiterte Suche. Like crypto. Data from a Phase 1 and a Phase 2a trial evaluating VK dosed subcutaneously for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. More recently, research efforts have explored the potential co-activation of the glucose-dependent insulinotropic peptide GIP receptor as a means of enhancing the therapeutic benefits of GLP-1 receptor activation. One patient receiving VK experienced a serious adverse event SAE of dehydration that was characterized as related to study drug. The primary endpoint of the study was the assessment of the percent change in body weight from baseline to Week 13 among patients treated with VK as compared with placebo, while secondary and exploratory endpoints evaluated a range of additional safety and efficacy measures. Statistically significant differences compared to both baseline and placebo were observed for all doses starting at Week one and continuing throughout the week treatment period. They can have huge rallies and complete reversals so it's important to take profits when you have them. Marktkapitalisierung: Mio.

Viking Therapeutics, Inc. The company was founded by Brian Lian and Michael A. This browser is no longer supported at MarketWatch.

Dividende je Aktie: -. Kurs: 1. Push Mitteilungen FN als Startseite. Indizes Indexliste. Aktien: Mean change from baseline body weight 4,5. This stock based on my technical analysis looks expensive for me to buy, I'm waiting for a huge retracement to the downside as there are tow gaps waiting to be filled. Reductions in body weight were progressive through the course of the study, with no plateau observed for weight loss at 13 weeks. Shooter: buy Viking Therapeutics Inc Sharewise. Notes: Safety population, includes all randomized subjects who received at least one dose of study drug.